Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 18;17(2):e1009323. doi: 10.1371/journal.pgen.1009323

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Yu et al

This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PMC Copyright notice

Fig 3 — This figure illustrates the top 20 drugs with the highest estimated prescription impact on headcount (left panel) and their respective predicted expenditure (right panel). Overall, most of the projected prescription impact was concentrated in a few drugs. The top three drugs projected to affect the greatest number of patients were the lipid-lowering drug simvastatin (146,167 patients, frequency: 25.81%), clopidogrel (26,304 patients, frequency: 57.21%), and anti-inflammatory drug ibuprofen (12,000 patients, frequency: 5.39%). It was estimated that 8,219,000 USD worth of drugs were prescribed to patients with an implicated actionable phenotype, where tacrolimus (4,301,000 USD), escitalopram (777,000 USD), and simvastatin (710,000 USD) accounted for 70.4% of the total expenditure. CPIC only recommends genotype-guided prescription of clopidogrel in patients with acute coronary syndrome receiving percutaneous coronary intervention. Indications for prescription is however not included in the CDARS system.